In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.45% at $3.41. This move lagged the S&P 500's daily gain of 0.29%. Elsewhere, the Dow saw a downswing of 0.31%, while the ...

Recursion Pharmaceuticals' AI-driven Recursion OS platform shows strong potential but has yet to demonstrate a clear ...

Penn Engineers have developed a new way to use AI to solve inverse partial differential equations (PDEs), a particularly ...

Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BSTSalt Lake City, UT, April 29, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio ...

Looking for non-Linux open-source options? From ghosts of past operating systems to fascinating works in progress, here are ...

A ripple tells you something happened, but not exactly what. That is the core problem behind a hard class of equations that ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.30, demonstrating a -3.23% change from the preceding day's closing price. This change lagged the S&P 500's 0.04% loss on the day ...

By combining professional-grade precision with an ultra-simple interface, Calculator+ ends the era of slow, ad-cluttered, and ...

Former employees at AI giants are raising hundreds of millions of dollars from investors months on from launching.

I took a shot and I wrote an article to a scientific journal, and next thing you know, it went through the peer review ...

However, a new study warns that the same capabilities driving their adoption are also creating a broad and evolving landscape of security, privacy, and ethical risks that existing safeguards are ...

ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.